在中国深圳湾区和美国硅谷湾区, 南科征途 Apostle 研发国际业界领先的原创性 cfDNA 技术,以应用于液体活检等临床检测领域。 Apostle 与国际生命科学领域的领导者之一,美国贝克曼库尔特 (Beckman Coulter)公司全球独家合作, 以自动或手动解决方案, 提供我们的专利技术 - 报道于 Science 杂志, 2019;364(6441):696, 新产品专题。

About


Background

Circulating free DNA (cfDNA) are degraded DNA fragments released to the blood plasma after diseased or normal cells die. cfDNA can be used to describe various forms of DNA freely circulating the bloodstream, including circulating tumor DNA (ctDNA) and cell-free fetal DNA (cffDNA) , and therefore, has become a biomarker for cancer and fetal medicine. In addition, it can be used for a wide range of conditions, including sepsis, aseptic inflammation, transplantation, etc.

A liquid biopsy is the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing cfDNA as a biomarker. A liquid biopsy has unleashed the potential to track and monitor important diseases, such as cancer, in a non-invasive and more effective manner.

Extensive scientific research has shown liquid biopsy to have important advantageous properties for clinical utility (e.g., most recently 1-4). Therefore, it has been named as a top breakthrough technology that will disrupt healthcare especially for cancer by the World Economic Forum (2017) 5, Forbes (2016) 6, and MIT Technology Review (2015) 7.

Vision

cfDNA is present in very small amounts in the blood plasma. Apostle develops a best-in-class technique 8-14, Apostle MiniMax TM, to efficiently capture this cfDNA from a standard blood draw, as well as other innovations in the space of liquid biopsy. We aim to improve the efficiency and accuracy of liquid biopsy, and consequently, improve the survival rate of patients.

Apostle MiniMax image

References

[About Liquid Biopsy]

  1. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Parikh et al. Nature Medicine. 25, 1415–1421 (2019)
  2. Genome-wide cell-free DNA fragmentation in patients with cancer. Cristiano et al. Nature. 570, 385–389 (2019)
  3. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Cohen et al. Science. 359, 926-930 (2018)
  4. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Shen et al. Nature. 563, 579–583 (2018)
  5. These are the top 10 emerging technologies of 2017. World Economic Forum. Jun 26, 2017
  6. Five Technologies That Will Disrupt Healthcare By 2020. Forbes. Mar 30, 2016
  7. 10 Breakthrough Technologies 2015. MIT Technology Review. 2015

[About Apostle technologies]
Apostle technologies have been discussed or cited in the following publications:

  1. Cell-Free DNA Isolation Kit. Science. 17 May 2019:Vol. 364, Issue 6441, pp. 696. DOI: 10.1126/science.364.6441.696-a. (Featured in New Products section)
  2. Enrichment of cell-free fetal DNA (cffDNA) from maternal plasma on a nanotechnology platform. Zhang et al. Manuscript under review.
  3. G3viz: an R package to interactively visualize genetic mutation data using a lollipop-diagram. Xin G, Bo Z, Wenqi Z, et al. Bioinformatics. 2020; 36(3):928–929,
  4. Correlation between mutations found in FFPE tumor tissue and paired cfDNA samples. Niccum B., Heath C., Saunders L., Hur A.,Patel A. Association for Molecular Pathology (AMP). (abstract #ST103). Baltimore, MD. November 7-9, 2019
  5. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study. Yang et al. Targeted Oncology. 2019;14:719-728. Published: 06 November 2019.
  6. Correlation between mutations found in FFPE tumor tissue and paired cfDNA samples. (n=8) Niccum B., Saunders L., Hur A.,Patel A. The American Society of Human Genetics (ASHG). (abstract #1766). Houston, TX. Oct 15, 2019
  7. Comparison between mutation profiles of paired whole blood and cfDNA samples. Patel A., Saunders L., Hur A. The American Society of Human Genetics (ASHG). (abstract #1767). Houston, TX. Oct 15, 2019
  8. Isolation of cell-free DNA (cfDNA) from plasma using Apostle MiniMaxTM High Efficiency cfDNA Isolation kit—comparison of fully automated, semi-automated and manual workflow processing. Brittany Niccum, PhD., Randy Pares and Antonia Hur. Beckman Coulter Life Sciences. Application Note. Sept 2019.
  9. A workflow for medium-throughput isolation of cfDNA from plasma samples using Apostle MiniMaxTM on the KingFisherTM Technology. Brittany Niccum, PhD. Beckman Coulter Life Sciences. Application Note. 2019.
  10. Correlation between mutations found in FFPE tumor tissue and paired cfDNA samples. (n=3) Saunders L and Patel A. American Association for Cancer Research (AACR). (abstract #2233). Atlanta, GA. April 2, 2019
  11. A new Scalable and automatable method for the extration of cfDNA. Saunders LP, Hur A, Niccum B, and Patel A. Advances in Genome Biology and Technology (AGBT). (abstract #419). Marco Island, FL. Feb 28, 2019
  12. cfDNA Extraction from Plasma for Liquid Biopsy: Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit. Beckman Coulter Life Sciences, Data Sheet. 2019.

新闻


2020
二月
13
Apostle Inc 将于2020年6月美国西雅图液体活检峰会做大会报告
Apostle Inc 获选于2020年6月15-17日美国西雅图召开的第五届液体活检峰会(the 5th Liquid Biopsy Summit)上做大会演讲报告。 公司董事长葛东亮博士将汇报 Apostle MiniEnrich, 一种全新的用于下一代无创产检和肿瘤检测应用的短片段游离核酸精细分离技术。 read more
2020
一月
27
Apostle Inc 聘任 Antonius ‘Toni’ Schuh 博士为顾问团成员
Apostle Inc 聘任 Antonius ‘Toni’ Schuh 博士为顾问团成员。 Toni是传奇式的连续创业者和科学家,曾创办生命科学领域5家公司并担任CEO,其中3家在纳斯达克上市。 read more
2020
一月
23
Apostle Inc 在全球精准医学大会作主题报告
Apostle Inc 在位于美国加州圣克拉拉会议中心的全球精准医学大会 PMWC20 作主题报告。 read more